Markets News
Earnings1 min read
Evotec Keeps 2026 Forecast Despite Expected Nine-Month Beat
The drug developer still expects an annual adjusted operating loss, while its estimated first-nine-month figures exceed market expectations.
Key takeaways
- Evotec maintained its 2026 revenue and adjusted EBITDA forecast.
- The company expects nine-month revenue of €465 million and adjusted EBITDA of minus €42.8 million.
- Evotec said the estimated nine-month figures exceed current market expectations, mainly because of the timing of consensus estimates.
Evotec maintained its 2026 forecast, projecting revenue of €570 million to €610 million and adjusted EBITDA of minus €70 million to minus €105 million. The drug developer said it had lowered the outlook in mid-July.
For the first nine months, Evotec expects revenue of €465 million and adjusted EBITDA of minus €42.8 million. The company said both figures would be above current market expectations.
Evotec attributed most of the difference to the timing of consensus estimates.
Topics
Further reading
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.
